Sangamo Therapeutics, Inc. (NASDAQ:SGMO) VP Curt A. Herberts III sold 11,803 shares of the stock in a transaction on Monday, December 4th. The shares were sold at an average price of $18.00, for a total value of $212,454.00. Following the completion of the sale, the vice president now owns 27,636 shares in the company, valued at $497,448. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Curt A. Herberts III also recently made the following trade(s):

  • On Friday, December 1st, Curt A. Herberts III sold 16,630 shares of Sangamo Therapeutics stock. The shares were sold at an average price of $16.13, for a total value of $268,241.90.

Shares of Sangamo Therapeutics, Inc. (SGMO) traded down $0.10 during mid-day trading on Wednesday, hitting $16.35. The company’s stock had a trading volume of 1,735,124 shares, compared to its average volume of 1,314,902. Sangamo Therapeutics, Inc. has a 12 month low of $2.65 and a 12 month high of $18.40. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.64 and a current ratio of 5.64.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.04. The company had revenue of $11.81 million for the quarter, compared to analyst estimates of $10.37 million. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The business’s quarterly revenue was up 333.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.27) earnings per share. analysts predict that Sangamo Therapeutics, Inc. will post -0.73 earnings per share for the current year.

SGMO has been the topic of a number of analyst reports. ValuEngine upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Piper Jaffray Companies set a $8.00 price target on Sangamo Therapeutics and gave the company a “hold” rating in a research note on Thursday, August 10th. Barclays initiated coverage on Sangamo Therapeutics in a research note on Wednesday, November 22nd. They issued an “overweight” rating and a $20.00 price target on the stock. Zacks Investment Research upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research note on Friday, August 18th. Finally, Wedbush restated a “hold” rating and issued a $6.00 price target on shares of Sangamo Therapeutics in a research note on Wednesday, November 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $17.83.

Hedge funds have recently modified their holdings of the business. Cookson Peirce & Co. Inc. purchased a new position in shares of Sangamo Therapeutics during the second quarter worth about $317,000. State Street Corp grew its holdings in shares of Sangamo Therapeutics by 51.6% during the second quarter. State Street Corp now owns 1,868,285 shares of the biopharmaceutical company’s stock worth $16,441,000 after purchasing an additional 636,296 shares during the last quarter. Swiss National Bank grew its holdings in shares of Sangamo Therapeutics by 26.4% during the second quarter. Swiss National Bank now owns 143,560 shares of the biopharmaceutical company’s stock worth $1,263,000 after purchasing an additional 30,000 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Sangamo Therapeutics by 53.5% during the second quarter. Goldman Sachs Group Inc. now owns 100,176 shares of the biopharmaceutical company’s stock worth $881,000 after purchasing an additional 34,913 shares during the last quarter. Finally, Wells Fargo & Company MN grew its holdings in shares of Sangamo Therapeutics by 45.8% during the second quarter. Wells Fargo & Company MN now owns 431,234 shares of the biopharmaceutical company’s stock worth $3,795,000 after purchasing an additional 135,464 shares during the last quarter. 64.35% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2017/12/06/sangamo-therapeutics-inc-sgmo-vp-curt-a-herberts-iii-sells-11803-shares.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.